Biogen Inc unchanged

Biogen Inc is unchanged Thursday sitting at (U.S.)$289.54. Over the last five days, shares have lost 2.57% and are down 5.49% for the last year to date. This security has underperformed the S&P 500 by 7.97% during the last year.

Key company metrics

Open(U.S.) $0.00

Previous close(U.S.) $289.54

High--

Low--

Bid / Ask(U.S.) $305.00 / (U.S.) $305.50

YTD % change-5.49%

Volume215,327

Average volume (10-day)1,884,003

Average volume (1-month)1,871,173

Average volume (3-month)1,583,896

52-week range(U.S.) $223.02 to (U.S.) $333.65

Beta0.73

Trailing P/E16.37×

P/E 1 year forward14.34×

Forward PEG1.59×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) $17.69

Updated December 8 4:00 PM EST. Delayed by at least 15 minutes.

Key company metrics

Open(U.S.) $0.00

Previous close(U.S.) $289.54

High--

Low--

Bid / Ask(U.S.) $305.00 / (U.S.) $305.50

YTD % change-5.49%

Volume215,327

Average volume (10-day)1,884,003

Average volume (1-month)1,871,173

Average volume (3-month)1,583,896

52-week range(U.S.) $223.02 to (U.S.) $333.65

Beta0.73

Trailing P/E16.37×

P/E 1 year forward14.34×

Forward PEG1.59×

Indicated annual dividend--

Dividend yield0.00%

Trailing EPS(U.S.) $17.69

Updated December 8 4:00 PM EST. Delayed by at least 15 minutes.

About

Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients

Continue reading

for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.

Restrictions

All rights reserved. Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. Thomson Reuters is not liable for any errors or delays in Thomson Reuters content, or for any actions taken in reliance on such content. ‘Thomson Reuters’ and the Thomson Reuters logo are trademarks of Thomson Reuters and its affiliated companies.